Skip to main content
Figure 5 | Molecular Neurodegeneration

Figure 5

From: Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575

Figure 5

LY-411575 treatment reduced soluble and insoluble Aβ40 and 42 brain levels in APPswe/PS1dE9xYFP mice. All measurements were done in triplicate and data are representative of 4–6 mice. Student-t test for independent samples showed a significant reduction of soluble and insoluble Aβ40 and 42 brain levels after 3 weeks of treatment when compared with control values (*p < 0.05).

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326